ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies
Cancer Drug Resistance · 23.05.2024
DOI: 10.20517/cdr.2024.25 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, online erschienen am 23.05.2024. Verfasst von Darin Poei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Southern California, Los Angeles, CA 90033, USA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Anaplastic lymphoma kinase (ALK ) gene rearrangements have been identified as potent oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC). The discovery of ALK inhibition using a tyrosine kinase inhibitor (TKI) has dramatically improved the outcomes of patients with ALK-mutated NSCLC. However, the emergence of intrinsic and acquired resistance inevitably occurs with ALK TKI use. This review describes the molecular mechanisms of ALK TKI resistance and discusses management strategies to overcome therapeutic resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Southern California, Los Angeles, CA 90033, USA.
- Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Zitieren
APA
Poei, D., Ali, S., Ye, S., & Hsu, R. (2024). ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2024.25
Vancouver
Poei D, Ali S, Ye S, Hsu R. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies. Cancer Drug Resistance. 2024. doi:10.20517/cdr.2024.25
BibTeX
@article{Poei2024,
author = {Poei, Darin and Ali, Sana and Ye, Shirley and Hsu, Robert},
title = {ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies},
journal = {Cancer Drug Resistance},
year = {2024},
doi = {10.20517/cdr.2024.25}
}
EUVIMED